Detailed price information for Vertex Inc Cl A (VERX-Q) from The Globe and Mail including charting and trades.

Savara advances BLA plans with strong molgramostim data, large aPAP market potential, and a reinforced cash position. Find ...

Abstract: 3-path vertex cover of networks is a typical optimization problem in network science, which has a wide range of applications. Toward a 3-path vertex cover of networks from distributed ...

As the U.S. stock market navigates a mixed landscape with tech shares rebounding and the Dow Jones Industrial Average experiencing declines, investors are closely watching for opportunities amid ...

Vertex, Inc. (NASDAQ: VERX) posted double-digit revenue growth in the third quarter of 2025 and announced its first-ever ...

Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and ...

Google Cloud has rolled out a series of updates to its Vertex AI Agent Builder in the hope that developers continue to build, test and deploy AI agents on its platform, with an emphasis on faster ...

Eli Lilly’s star oral GLP-1 candidate orforglipron and Novo Nordisk’s Wegovy (semaglutide) were named voucher winners in a ...

Google Cloud expanded features of its Agent Builder platform focusing on orchestration, observability and monitoring for the ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.